Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Russian Blitz, Glenmark Peek Await Indian Biosimilars Arena

Executive Summary

Potential new entrants appear to be priming varied approaches to the competitive biosimilars market in India. While a full-fledged Russian challenge may be on the horizon as Biocad readies a basket of products for the Indian market, local firm Glenmark, which has been keen to stay focused on new biological entities (NBEs), now appears to be dipping its toe into the biosimilars segment.

You may also be interested in...

Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad

Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.

INTERVIEW: Glenmark's Buschle on how it hopes to 'BEAT' cancer

Michael Buschle, Glenmark's chief scientific officer and president (biologics), clearly values the Indian firm's "entrepreneurial culture" and "flexibility", even if it means doing cutting edge R&D with relatively smaller budgets than Big Pharma enjoys.

Four brands but no MabThera in Indian rituximab market flux

Evolving strategies and competition appear to have contributed to significant tweaks on the Indian market for rituximab – currently in the spotlight with the entry of the local firm, Intas, with its biosimilar version of the monoclonal antibody.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts